Currently, for further improved survival outcome, new cytotoxic compounds such as irinotecan
and docetaxel have been combined with 5-FU/cisplatin. However, triplet regimen often burdened
with higher toxicity and serious neutropenic infection. Therefore, future trials in
neoadjuvant and adjuvant settings need to incorporate new molecular agents which improve
efficacy, but less toxicity.